Experimental HCV Drugs
Experimental HCV Drugs
DDW 2013: Advanced Fibrosis Does Not Affect Response to Faldaprevir All-oral Regimen
- Details
- Category: HCV Treatment
- Published on Wednesday, 22 May 2013 00:00
- Written by Liz Highleyman
TEXT
HCV Protease Inhibitor Simeprevir Granted FDA Priority Review Status
- Details
- Category: HCV Treatment
- Published on Wednesday, 15 May 2013 00:00
- Written by Janssen
On May 13, Janssen announced that its application for approval of the next-generation hepatitis C virus NS3/4A protease inhibitor simeprevir (formerly TMC435) has received priority review status from the U.S. Food and Drug Administration (FDA), giving it an estimated timeline of 6 months.
EASL 2013: ACH-3102 and Sovaprevir Show Potent Activity, High Barrier to Resistance in Early Studies
- Details
- Category: HCV Treatment
- Published on Friday, 10 May 2013 00:00
- Written by Liz Highleyman
Achillion Pharmaceuticals' second-generation NS5A inhibitor ACH-3102 demonstrated potent activity against genotype 1a and 1b hepatitis C virus (HCV) and can be safely co-administered with the company's investigational protease inhibitor sovaprevir (formerly ACH-1625), according to studies presented at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.
EASL 2013: Direct-acting Antivirals Boost Response to Pegylated Interferon/Ribavirin
- Details
- Category: HCV Treatment
- Published on Wednesday, 15 May 2013 00:00
- Written by Liz Highleyman
For people with chronic hepatitis C who cannot wait for all-oral regimens, interferon-based therapy is still a reality. Researchers at the recent EASL International Liver Congress (EASL 2013) presented promising data showing that several experimental direct-acting antiviral agents (DAAs) can significantly improve response rates without reducing tolerability.
Sofosbuvir/Ledipasvir Coformulation Shows Good Early Response With or Without Ribavirin
- Details
- Category: HCV Treatment
- Published on Friday, 10 May 2013 00:00
- Written by Liz Highleyman
A dual regimen of sofosbuvir (formerly GS-7977) plus ledipasvir (formerly GS-5885) for 8 or 12 weeks produced 4-week post-treatment sustained virological response (SVR4) rates of 95% to 100% for both treatment-naive and previously treated hepatitis C patients in a small Phase 2 study, according to a recent announcement from Gilead Sciences, developer of both drugs.
More Articles...
- Direct-acting Antivirals Could Dramatically Reduce Hepatitis C Transmission among IDUs
- EASL 2013: Vaniprevir Boosts Interferon/Ribavirin Response Rate for Prior Non-Responders with Cirrhosis
- AbbVie Interferon-free Hepatitis C Combo Gets FDA 'Breakthrough' Status
- EASL 2013: Compassionate Access to New Hepatitis C Drugs Is an 'Emergency' for European Patients
Web Design and Development by